Business
HCW Biologics Announces 1-for-40 Reverse Stock Split
MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock, par value $0.0001 (“Common Stock”), which will be effective at 1
About this update from Hcw Biologics Inc.
[{"type":"image","alt":"HCW Biologics, Inc","displaySize":"","headline":null,"caption":"HCW Biologics, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8op9ybYTjyQdFXiaAcCiSw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/41c465fea041fccd686f09c17f724fb7","width":300,"height":150}},"lazy":false},{"type":"text","content":"MIRAMAR, Fla., April 01, 2025 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock, par value $0.0001 (“Common Stock”), which will be effective at 12:01 a.m. Eastern Time on April 11, 2025. The Company’s Common Stock will be traded on The Nasdaq Capital Market on a reverse split-adjusted basis beginning on April 11, 2025, under the Company’s existing trading symbol “HCWB.”","length":727,"tagName":"p"},{"type":"text","content":"The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company’s Common Stock for continued listing on The Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 40423R204. The Company filed the relevant amendments to its Certificate of Incorporation with the Delaware Secretary of State on March 31, 2025 and April 1, 2025 to effect the reverse split.","length":450,"tagName":"p"},{"type":"text","content":"The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage ownership interest in the Company, except to the extent that the reverse stock split would otherwise result in any of the Company’s stockholders owning a fractional share as described in more detail below.","length":316,"tagName":"p"},{"type":"text","content":"The reverse stock split will reduce the number of shares of Common Stock issued and outstanding from 44,934,120 to approximately 1,123,353. The total authorized number of shares of ...